The Interplay Between Neuroendocrıne Hormıones, Proteomıc Bıomarkers, and Altered Bıochemıcal Pathways in Esophageal Adenocarcınoma and Squamous Cell Carcınoma

Esophageal cancer remains a highly aggressive gastrointestinal malignancy with a dismal prognosis worldwide. It is characterized primarily by two distinct histological subtypes: Esophageal Squamous Cell Carcinoma (ESCC) and Esophageal Adenocarcinoma (EAC). While ESCC is epidemiologically linked to tobacco smoke and alcohol consumption, EAC is closely associated with obesity, gastroesophageal reflux disease (GERD), and Barrett’s esophagus (BE). Despite their distinct etiologies, both subtypes undergo severe molecular alterations that involve neuroendocrine shifting, altered systemic proteomic networks, and metabolic reprogramming. Traditional staging relies heavily on invasive tissue biopsies, emphasizing the critical need for non-invasive, blood-based multi-analyte monitoring. This comprehensive academic review systematically evaluates the intricate interplay between neuroendocrine hormones, functional proteomic biomarkers, and altered biochemical pathways in ESCC and EAC to outline novel diagnostic panels and targeted therapeutic strategies. A methodical review of peer-reviewed articles, clinical trials, and multi-omics validation cohorts published up to late 2026 was performed using specialized databases including PubMed, Web of Science, and Google Scholar. Structural query configurations combined targeted strings: ("esophageal squamous cell carcinoma" OR "esophageal adenocarcinoma") AND ("neuroendocrine hormones" OR "proteomics") AND ("biochemical pathways" OR "leptin" OR "adiponectin" OR "S100A8"). Interventions investigating generalized gastric or intestinal malignancies without sub-classified esophageal longitudinal validation data were excluded. The biochemical landscapes of ESCC and EAC reveal distinct enzymatic and systemic networks. In EAC, visceral obesity drives a prominent adipokine imbalance. Hypertrophic adipocytes overproduce the pro-inflammatory hormone leptin while suppressing high-molecular-weight (HMW) adiponectin. Elevated leptin binds to its receptor (Ob-R), stimulating Jan kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3) and mitogen-activated protein kinase (MAPK) cascades, which accelerate tumor proliferation and suppress pyroptosis. Conversely, adiponectin acts as a critical tumor suppressor, but its systemic depletion promotes tumor migration. In ESCC, serum proteomic profiling reveals a distinct up-regulation of the S100A8/A9 complex, Alpha-1-Acid Glycoprotein 1 (SAA1), and key glycolytic enzymes such as Enolase 1 (ENO1). These altered proteomic networks mirror the systemic Warburg effect, where carbohydrate utilization is heavily reduced in favor of accelerated amino acid and sphingolipid catabolism. Furthermore, both subtypes exhibit variable neuroendocrine features; advanced neuroendocrine differentiation correlates with heightened tumor invasion, neoangiogenesis via vascular endothelial growth factor A (VEGF-A), and resistance to standard fluorouracil-based chemotherapies. Esophageal malignancies are driven by a dynamic web of hormonal dysregulation, proteomic shifts, and metabolic adaptations. Transitioning from standalone diagnostic metrics toward multi-analyte panels that combine adipokine ratios (leptin/adiponectin), specific serum proteins (S100A8, ENO1), and angiogenic parameters offers a powerful, non-invasive platform for early detection, prognosis tracking, and personalized target selection.